Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted
File(s)
Author(s)
Type
Journal Article
Abstract
Antifibrotic drugs for idiopathic pulmonary fibrosis patients in England and Scotland are only available to those with FVC percent predicted (FVC%pred) less than or equal to 80%. The prescribing guidance does not state which set of reference values should be used and we show that a patient's FVC%pred can change by 4–6% depending on the choice of reference. We calculated FVC%pred for a group of 528 IPF patients using three different sets of reference values. 90% of patients with FVC%pred 80–85% calculated using European Community Coal and Steel (ECSC) reference values fall into the eligible range when NHANES reference values are used.
Date Issued
2016-10-14
Date Acceptance
2016-10-12
Citation
Respiratory Medicine, 2016, 120, pp.131-133
ISSN
0954-6111
Publisher
Elsevier
Start Page
131
End Page
133
Journal / Book Title
Respiratory Medicine
Volume
120
Copyright Statement
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Sponsor
NIHR Research for Patient Benefit Programme
Grant Number
PB-PG-0712-28073
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Respiratory System
Cardiovascular System & Cardiology
Respiratory function tests
Idiopathic pulmonary fibrosis
Interstitial lung disease
LUNG-FUNCTION
EQUATIONS
Publication Status
Published